vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Claritev Corp (CTEV). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $183.1M, roughly 1.3× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -32.7%, a 46.0% gap on every dollar of revenue. On growth, Claritev Corp posted the faster year-over-year revenue change (6.2% vs -1.8%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 2.5%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AMPH vs CTEV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $246.6M |
| Net Profit | $24.4M | $-80.6M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -3.1% |
| Net Margin | 13.3% | -32.7% |
| Revenue YoY | -1.8% | 6.2% |
| Net Profit YoY | -35.7% | 41.6% |
| EPS (diluted) | $0.51 | $-4.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $246.6M | ||
| Q3 25 | $191.8M | $246.0M | ||
| Q2 25 | $174.4M | $241.6M | ||
| Q1 25 | $170.5M | $231.3M | ||
| Q4 24 | $186.5M | $232.1M | ||
| Q3 24 | $191.2M | $230.5M | ||
| Q2 24 | $182.4M | $233.5M | ||
| Q1 24 | $171.8M | $234.5M |
| Q4 25 | $24.4M | $-80.6M | ||
| Q3 25 | $17.4M | $-69.8M | ||
| Q2 25 | $31.0M | $-62.6M | ||
| Q1 25 | $25.3M | $-71.3M | ||
| Q4 24 | $38.0M | $-138.0M | ||
| Q3 24 | $40.4M | $-391.4M | ||
| Q2 24 | $37.9M | $-576.7M | ||
| Q1 24 | $43.2M | $-539.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -3.1% | ||
| Q3 25 | 13.2% | 4.1% | ||
| Q2 25 | 24.2% | 6.9% | ||
| Q1 25 | 21.9% | 4.2% | ||
| Q4 24 | 24.2% | -17.8% | ||
| Q3 24 | 29.8% | -146.7% | ||
| Q2 24 | 30.3% | -224.4% | ||
| Q1 24 | 27.9% | -207.4% |
| Q4 25 | 13.3% | -32.7% | ||
| Q3 25 | 9.0% | -28.4% | ||
| Q2 25 | 17.8% | -25.9% | ||
| Q1 25 | 14.8% | -30.8% | ||
| Q4 24 | 20.4% | -59.4% | ||
| Q3 24 | 21.1% | -169.8% | ||
| Q2 24 | 20.8% | -247.0% | ||
| Q1 24 | 25.1% | -230.1% |
| Q4 25 | $0.51 | $-4.88 | ||
| Q3 25 | $0.37 | $-4.23 | ||
| Q2 25 | $0.64 | $-3.81 | ||
| Q1 25 | $0.51 | $-4.38 | ||
| Q4 24 | $0.74 | $-8.49 | ||
| Q3 24 | $0.78 | $-24.25 | ||
| Q2 24 | $0.73 | $-35.78 | ||
| Q1 24 | $0.81 | $-33.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $16.8M |
| Total DebtLower is stronger | $608.7M | $4.6B |
| Stockholders' EquityBook value | $788.8M | $-173.9M |
| Total Assets | $1.6B | $4.9B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $16.8M | ||
| Q3 25 | $276.2M | $39.2M | ||
| Q2 25 | $231.8M | $56.4M | ||
| Q1 25 | $236.9M | $23.1M | ||
| Q4 24 | $221.6M | $16.8M | ||
| Q3 24 | $250.5M | $86.6M | ||
| Q2 24 | $217.8M | $48.8M | ||
| Q1 24 | $289.6M | $58.7M |
| Q4 25 | $608.7M | $4.6B | ||
| Q3 25 | $608.6M | $4.5B | ||
| Q2 25 | $607.7M | $4.5B | ||
| Q1 25 | $603.9M | $4.5B | ||
| Q4 24 | $601.6M | $4.5B | ||
| Q3 24 | $596.4M | $4.5B | ||
| Q2 24 | $586.9M | $4.5B | ||
| Q1 24 | $594.0M | $4.5B |
| Q4 25 | $788.8M | $-173.9M | ||
| Q3 25 | $776.7M | $-101.8M | ||
| Q2 25 | $757.5M | $-39.9M | ||
| Q1 25 | $751.3M | $14.8M | ||
| Q4 24 | $732.3M | $84.0M | ||
| Q3 24 | $727.7M | $207.6M | ||
| Q2 24 | $713.3M | $603.4M | ||
| Q1 24 | $672.4M | $1.2B |
| Q4 25 | $1.6B | $4.9B | ||
| Q3 25 | $1.7B | $5.0B | ||
| Q2 25 | $1.6B | $5.1B | ||
| Q1 25 | $1.6B | $5.1B | ||
| Q4 24 | $1.6B | $5.2B | ||
| Q3 24 | $1.5B | $5.3B | ||
| Q2 24 | $1.5B | $5.7B | ||
| Q1 24 | $1.6B | $6.4B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | 304.87× | ||
| Q4 24 | 0.82× | 53.67× | ||
| Q3 24 | 0.82× | 21.73× | ||
| Q2 24 | 0.82× | 7.48× | ||
| Q1 24 | 0.88× | 3.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $66.3M |
| Free Cash FlowOCF − Capex | $24.6M | $36.4M |
| FCF MarginFCF / Revenue | 13.4% | 14.8% |
| Capex IntensityCapex / Revenue | 4.5% | 12.1% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-12.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $66.3M | ||
| Q3 25 | $52.6M | $19.9M | ||
| Q2 25 | $35.6M | $61.2M | ||
| Q1 25 | $35.1M | $-30.1M | ||
| Q4 24 | $29.0M | $-33.4M | ||
| Q3 24 | $60.0M | $72.8M | ||
| Q2 24 | $69.1M | $18.5M | ||
| Q1 24 | $55.3M | $49.7M |
| Q4 25 | $24.6M | $36.4M | ||
| Q3 25 | $47.2M | $-16.3M | ||
| Q2 25 | $25.0M | $36.6M | ||
| Q1 25 | $24.4M | $-68.9M | ||
| Q4 24 | $16.6M | $-63.8M | ||
| Q3 24 | $46.2M | $41.1M | ||
| Q2 24 | $63.1M | $-7.0M | ||
| Q1 24 | $46.5M | $19.2M |
| Q4 25 | 13.4% | 14.8% | ||
| Q3 25 | 24.6% | -6.6% | ||
| Q2 25 | 14.3% | 15.2% | ||
| Q1 25 | 14.3% | -29.8% | ||
| Q4 24 | 8.9% | -27.5% | ||
| Q3 24 | 24.1% | 17.8% | ||
| Q2 24 | 34.6% | -3.0% | ||
| Q1 24 | 27.1% | 8.2% |
| Q4 25 | 4.5% | 12.1% | ||
| Q3 25 | 2.8% | 14.7% | ||
| Q2 25 | 6.1% | 10.2% | ||
| Q1 25 | 6.3% | 16.8% | ||
| Q4 24 | 6.7% | 13.1% | ||
| Q3 24 | 7.2% | 13.8% | ||
| Q2 24 | 3.3% | 10.9% | ||
| Q1 24 | 5.1% | 13.0% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CTEV
Segment breakdown not available.
